Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options

Keyphrases

• United States 100%
• Therapeutic Potential 100%
• Patient Selection 100%
• Chronic Hepatitis B Virus Infection 100%
• State Patient 100%
• Clinical Treatment 33%
• Early Treatment 33%
• Drug Resistance 33%
• Hepatocellular Carcinoma 33%
• Interferon-α (IFN-α) 33%
• Antiretroviral Therapy 33%
• Clinical Data 33%
• Clinical Trials 33%
• Family History 33%
• Clinical Practice 33%
• Expert Panel 33%
• Drug Development 33%
• Liver Disease 33%
• Liver Histology 33%
• Ultra-high Risk 33%
• Number of Drugs 33%
• Hepatitis B Virus DNA 33%
• Hepatitis B 33%
• Alanine Aminotransferase Level 33%
• Inappropriate Use 33%
• Treatment Decisions 33%
• Infections in children 33%
• Development Risk 33%
• Therapeutic Challenges 33%
• Resistance Development 33%
• Indications for Treatment 33%
• Treatment Timing 33%
• Conservative Approach 33%
• Hepatitis B Virus Therapy 33%
• Secondary Therapy 33%
• Pediatric Liver 33%
• Immune Active 33%
• Nucleos(t)ide Analogues 33%
• Inactive Carrier 33%
• Immune-tolerant Phase 33%
• Treatment Benefit 33%
• Immune Reactivation 33%
• Decision History 33%

Medicine and Dentistry

• Patient Selection 100%
• Hepatitis B Virus 100%
• Chronic Hepatitis B 100%
• Hepatocellular Carcinoma 50%
• Interferon 50%
• Pediatrics 50%
• Clinical Trial 50%
• Family History 50%
• Virus DNA 50%
• Liver Disease 50%
• Liver Histology 50%
• Drug Resistance 50%
• Alanine Aminotransferase 50%
• Hepatitis B 50%
• Virotherapy 50%
• Heterozygote 50%
• Antiviral Therapy 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Hepatitis B Virus 100%
• Chronic Hepatitis B 100%
• Clinical Trial 50%
• Interferon 50%
• Virus DNA 50%
• Drug Resistance 50%
• Hepatitis B 50%
• Liver Disease 50%
• Alanine Aminotransferase 50%
• Liver Cell Carcinoma 50%
• Virotherapy 50%
• Antiviral Therapy 50%